Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGC026 in Advanced Solid Tumors
NCT06242470Phase 1Recruiting
- Sponsor
- MacroGenics
- Start
- Mar 2024
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of MGC026 in solid tumor (16 arms), sponsored by MacroGenics. Primary endpoint: Adverse Events at 135 weeks. Started Mar 2024; status: recruiting.
02
Drugs
MGC026
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06242470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242470.